Eyes are an indispensable communication medium for human social interactions. Although previous neuroscientific evidence suggests the activation of the inferior occipital gyrus (IOG) during eye processing, the temporal profile of this activation remains unclear. To investigate this issue, we analyzed intracranial electroencephalograms of the IOG during the presentation of eyes and mosaics, in either averted or straight directions. Time-frequency statistical parametric mapping analyses revealed greater gamma-band activation in the right IOG beginning at 114 ms in response to eyes relative to mosaics, irrespective of their averted or straight direction. These results suggest that gamma oscillations in the right IOG are involved in the early stages of eye processing, such as eye detection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090864 | PMC |
| http://dx.doi.org/10.1038/srep36321 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Human cortical high-gamma power scales with movement rate in healthy participants and stroke survivors.
J Physiol
January 2025
Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Motor cortical high-gamma oscillations (60-90 Hz) occur at movement onset and are spatially focused over the contralateral primary motor cortex. Although high-gamma oscillations are widely recognized for their significance in human motor control, their precise function on a cortical level remains elusive. Importantly, their relevance in human stroke pathophysiology is unknown.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Universidad Complutense de Madrid, Madrid, Madrid, Spain.
Background: The preclinical stage of Alzheimer's disease (AD) has gained attention for the window of opportunity it opens for early detection and intervention. Given the high invasiveness of PET and CSF markers, electrophysiology and plasma biomarkers are being studied as alternate biomarkers for early detection and disease tracking. The aim of this study is twofold.
View Article and Find Full Text PDFBackground: Preclinical investigations in Alzheimer's disease (AD) have highlighted the efficacy of gamma sensory stimulation in mitigating AD-related pathologies. Cognito Therapeutics, Inc. (Cambridge, MA) has designed the Sensory Stimulation System for safe at-home usage, to induce EEG-confirmed gamma oscillations as a potential treatment for AD.
View Article and Find Full Text PDFBackground: In the EEG research of Alzheimer's Disease (AD) and other diseases belonging to dementia, the literature is rapidly growing to indicate biomarkers specific to the type of dementia. The literature showed firm conclusions that decreasing event-related delta and theta responses could be a biomarker showing cognitive decline (Güntekin et al. 2022).
View Article and Find Full Text PDFBackground: The OVERTURE (NCT03556280) randomized controlled trial (RCT) evaluated evoked gamma oscillation therapy using Cognito's medical device (CogTx-001) in mild-moderate Alzheimer's disease (AD). Brain atrophy, as measured by whole brain volume (WBV), is a key indicator of neurodegeneration in AD and may be influenced by baseline covariates such as age, disease stage, APOE4 carrier status, and PET amyloid levels, as well as treatment. We analyzed OVERTURE MRI whole brain volume outcomes across these key baseline subgroups.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!